Clinical trial
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly…
NCT00085254 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00085254 |
|---|---|
| Title | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
| Official title | A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma |
| Intervention type | Drug, Other, Radiation |
| Interventions | cilengitide, temozolomide, radiation therapy, laboratory biomarker analysis, pharmacological study |
| Enrollment | 112 |
| Start date | Apr 1, 2005 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Jun 11, 2004 |
| Last update posted | Feb 25, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: